HASUMI INTERNATIONAL RESEARCH FOUNDATION Patent applications |
Patent application number | Title | Published |
20150079032 | THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOTOXIC T LYMPHOCYTE AND ANTI-TNF ANTIBODY FOR TREATMENT OF TUMORS - The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy. | 03-19-2015 |
20150023997 | COMPOSITIONS, METHODS AND THERAPIES FOR ADMINISTERING ANTIGEN PEPTIDE - The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with | 01-22-2015 |
20140004126 | THERAPY AND METHOD FOR INTRATUMORALLY INTRODUCING CYTOTOXIC T LYMPHOCYTE AND/OR NKT CELL WITH ANTI-TNF AND/OR ANTI-IL-10 | 01-02-2014 |
20120071860 | DENDRITIC CELL TUMOR INJECTION (DCTI) THERAPY - The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with radiation therapy or a chemotherapy regimen. | 03-22-2012 |